Cart
sales@molnova.com
RAPTA-C
CAS No. 372948-28-2
RAPTA-C( —— )
Catalog No. M34689 CAS No. 372948-28-2
RAPTA-C induces EAC cell cycle arrest and apoptosis via the mitochondrial and p53-JNK pathways, and can be used in the study of breast and ovarian cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 160 | In Stock |
|
| 10MG | 236 | In Stock |
|
| 25MG | 404 | In Stock |
|
| 50MG | 574 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRAPTA-C
-
NoteResearch use only, not for human use.
-
Brief DescriptionRAPTA-C induces EAC cell cycle arrest and apoptosis via the mitochondrial and p53-JNK pathways, and can be used in the study of breast and ovarian cancer.
-
DescriptionRAPTA-C induces EAC cell cycle arrest and apoptosis via the mitochondrial and p53-JNK pathways, and can be used in the study of breast and ovarian cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number372948-28-2
-
Formula Weight463.35
-
Molecular FormulaC16H26Cl2N3PRu
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES[Cl-][Ru+2]12345([Cl-])([CH]=6[CH]5=C4(C(C)C)[CH]3=[CH]2C61C)[P]78CN9CN(CN(C9)C7)C8
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
KT5823
KT5823 is a selective and potent cGMP-dependent protein kinase (PKG) inhibitor with inhibitory effects on PKA and PKC.KT5823 increases thyroid-stimulating hormone-induced (Na+/I- symporter) NIS expression and iodide ion uptake by modulating sodium iodide symporter protein expression and activity in thyroid cells. KT5823 induces apoptosis.
-
Exisulind
Exisulind induces apoptosis through the activation of protein kinase G (PKG). Exisulind exhibits antineoplastic activity in solid tumour and haematological cancer cell lines and is an inhibitor of tumour growth in rodent models of colon, prostate, bladder, mammary and lung cancer.
-
Simmiparib
Simmiparib (SMOCL-9112) is a novel and potent PARP1 and PARP2 inhibitor, a derivative of Olaparib.
